SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Månsson L. K.) srt2:(2010-2014)"

Sökning: WFRF:(Månsson L. K.) > (2010-2014)

  • Resultat 1-2 av 2
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Lindblad, Ulf, 1950, et al. (författare)
  • Can sulphonylurea addition to lifestyle changes help to delay diabetes development in subjects with impaired fasting glucose? The Nepi ANtidiabetes StudY (NANSY)
  • 2011
  • Ingår i: Diabetes, Obesity and Metabolism. - Malden,USA : Wiley. - 1462-8902 .- 1463-1326. ; 13:2, s. 185-188
  • Tidskriftsartikel (refereegranskat)abstract
    • The Nepi ANtidiabetes StudY (NANSY) is a 5-year randomized, double-blind, placebo-controlled trial in Swedish primary care, examining whether the development of type 2 diabetes (T2D) and retinopathy (separately reported) would be delayed in 40- to 70-year-old subjects with impaired fasting glucose (IFG) who, in addition to lifestyle changes, were treated with either placebo or low-dosage sulphonylurea (SU) (1-mg glimepiride; Amaryl (R)). Of 274 subjects (163 men, 111 women), 138 were allocated to placebo (46.0% men, 56.8% women) and 136 to glimepiride (54.0% men, 43.2% women). The primary endpoint was conversion to diabetes. Average follow-up time was 3.71 years; 96 subjects converted to diabetes, 55 allocated to placebo and 41 to glimepiride (absolute difference 9.8%; p = 0.072). In conclusion, the study failed to support the notion that low-dose SU added to lifestyle changes in IFG subjects would help to delay the conversion to diabetes.
  •  
2.
  • Moyano, A. L., et al. (författare)
  • Levels of plasma sulfatides C18: 0 and C24: 1 correlate with disease status in relapsing-remitting multiple sclerosis
  • 2013
  • Ingår i: Journal of Neurochemistry. - : Wiley. - 0022-3042. ; 127:5, s. 600-604
  • Tidskriftsartikel (refereegranskat)abstract
    • Multiple sclerosis (MS) is considered an autoimmune demyelinating disease of the CNS and myelin-derived glycolipids are one of the targets of this autoimmune attack. In this study, we examined for the first time the plasma distribution of sulfatide isoforms. Sulfatides with long-chain (C24:0 or C24:1) and short-chain (C16:0 or C18:0) fatty acids were quantified in plasma of relapsing-remitting MS patients by ultra-high-performance liquid chromatography tandem mass spectrometry. We found that C18:0 and C24:1 sulfatide plasma levels positively correlated with the Expanded Disability Status Scale. C16/C18:0 and C16/C24:0 ratios also correlated with the age and the time since last relapse. Healthy women showed higher levels of C16:0 sulfatide than healthy men; however, this gender difference disappeared in MS patients. Our data underline the potential use of sulfatides as biomarkers in relapsing-remitting MS and points to a possible association with the higher susceptibility of women to develop MS.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-2 av 2

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy